Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature.

Journal Article (Clinical Trial;Journal Article;Review)

Our aim was to investigate the long term effectiveness of intravenous immunoglobulin (IVIG) against intractable childhood epilepsy in the era of new antiepileptics and to determine the predictors of a favorable response in a prospective open-label add-on study. Of thirty-seven 9.9+/-0.9-year-old patients (11 with partial seizures, 26 with generalized seizures of whom 9 had West syndrome and 17 Lennox-Gastaut syndrome) followed for 15+/-3 months, 43% had a >50% decrease in seizures (including 15% seizure free, 229+/-58 compared with 104+/-3 seizures/month, P=0.035: generalized 246+/-318 to 117+/-200, P=0.025, partial 191+/-437 to 72+/-179, P>0.05; power=0.2). Males were more likely to respond than females (P=0.011, odds ratio=9.3). Review of the literature revealed nine other articles reporting efficacy of IVIG against epileptic seizures. Only one other used statistical methods and, unlike ours, showed only a trend toward seizure frequency reduction without achieving statistical significance, presumably because it was underpowered. These results indicate large-scale controlled studies of IVIG in epilepsy are still needed.

Full Text

Duke Authors

Cited Authors

  • Mikati, MA; Kurdi, R; El-Khoury, Z; Rahi, A; Raad, W

Published Date

  • January 2010

Published In

Volume / Issue

  • 17 / 1

Start / End Page

  • 90 - 94

PubMed ID

  • 20004620

Electronic International Standard Serial Number (EISSN)

  • 1525-5069

Digital Object Identifier (DOI)

  • 10.1016/j.yebeh.2009.10.020


  • eng

Conference Location

  • United States